On September 29, JD HEALTH rose 3.1% in regular trading, trading at 36.58 HKD/share, with turnover of approximately 59.14 million HKD. The move was driven by the announcement that JD HEALTH and GE Healthcare signed a strategic cooperation agreement on September 28, with both parties set to further explore digital operation pathways for medical device products.

Beyond the GE Healthcare deal, JD HEALTH has been accelerating its ecosystem expansion in recent weeks, inking strategic partnerships with BGI Genomics in genetic testing, Kindway subsidiary Dr. Pets in nutrition and health quality co-development, Jointown Pharmaceutical in supply chain collaboration, and Likang Life Sciences in mRNA tumor therapy. The company also showcased its full-scenario AI plus medical-examination-diagnosis-medication service loop at a trade fair earlier this month.

Fundamentally, JD HEALTH reported H1 revenue of RMB 40.9 billion, up 15.9% year-over-year, with adjusted net profit of RMB 3.5 billion, surging 40.3%. Operating margin improved from 7.0% to 8.5%. The company launched 65 new drugs in the first half and expanded its self-operated pharmacy network to over 450 stores nationwide.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)